Paxil (paroxetine) is a member of the class of medicines called Selective Serotonin Reuptake Inhibitors (SSRIs). Paxil is manufactured by GlaxoSmithKline. It is an antidepressant prescribed for major depressive disorder, social anxiety disorder, generalized anxiety, obsessive compulsive disorder and post-traumatic stress.
In December of 2005, the FDA issued a Public Health Advisory, advising against the use of paroxetine, such as Paxil, during pregnancy. Several studies done showed that women who received paroxetine in early pregnancy had an increased risk for having an infant with a heart defect and congenital malformations. The Public Health Advisory also stated that physicians should encourage pregnant patients to discontinue use of paroxetines. In July of 2006, the FDA issued an alert to healthcare providers, advising that the results of a study of infants born to mothers who took SSRIs during pregnancy revealed that the infants were six times more likely to have persistent pulmonary hypertension (PPHN) than those infants whose mothers did not take SSRIs during pregnancy. PPHN is a serious and life-threatening lung condition that occurs shortly after birth.
The following injuries or symptoms in infants have been associated with a mother’s prenatal use of Paxil:
- Persistent Pulmonary Hypertension (PPHN)
- Heart defects, such as atrial or ventricular septal defects, which are conditions in which the wall between the right and left sides of the heart is not completely developed
- Craniosynostosis, which is an abnormally shaped skull
- Limb reduction
- Omphalocele, a birth defect in which abdominal contents remain outside of the abdomen
Suthers Law Firm is investigating cases involving infants who are exposed to Paxil within all trimesters of pregnancy and have suffered birth defects, including, but not limited, those list above. If your infant or the infant of someone you know has experienced any of the conditions listed above, contact us online or call us on our toll free number, 1-800-320-2384, to set up a FREE consultation.